middle.news
How Paradigm’s $41M Boost Fuels Its Global Osteoarthritis Trial Surge
9:35am on Tuesday 29th of July, 2025 AEST
•
Healthcare
Read Story
How Paradigm’s $41M Boost Fuels Its Global Osteoarthritis Trial Surge
9:35am on Tuesday 29th of July, 2025 AEST
Key Points
Phase 3 trial recruitment underway at 27 sites across Australia and the US
Secured US$27 million convertible note facility with Obsidian Global Partners
Acquisition of Proteobioactives and Pentacoxib™ IP broadens osteoarthritis pipeline
Cash balance of A$16.82 million at quarter-end with full funding through mid-2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE